Pharming Group N.V annual operating cash flow
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Operating Cash Flow Growth & History (PHAR)
Pharming Group N.V's operating cash flow was $54.7M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $54.7M | $56.5M | — |
| 2024 | 2024-12-31 | −$1.8M | $15.5M | — |
| 2023 | 2023-12-31 | −$17.3M | −$39.8M | — |
| 2022 | 2022-12-31 | $22.5M | −$15.4M | −40.65% |
| 2021 | 2021-12-31 | $37.8M | −$45.8M | −54.75% |
| 2020 | 2020-12-31 | $83.6M | $9.5M | +12.78% |
| 2019 | 2019-12-31 | $74.1M | — | — |
Pharming Group N.V quarterly operating cash flow
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$9.7M | −$21.4M | — |
| Q1 2026 | 2026-03-31 | $2.0M | — | — |
| Q4 2025 | 2025-12-31 | $10.7M | — | — |
| Q3 2025 | 2025-09-30 | $32.0M | — | — |
| Q2 2025 | 2025-06-30 | $11.7M | — | — |
Pharming Group N.V operating cash flow trends
Over the last five fiscal years, Pharming Group N.V's operating cash flow decreased from $83.6M to $54.7M, a change of −$28.9M. The latest reported quarter, Q2 2026, shows −$9.7M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...